Page 138 - 《中国药房》2023年9期

to simvastatin treatment[J]. J Cardiovasc Pharmacol， genet Genomics，2017，27（8）：285-293.
2020，75（2）：168-173. [36] ZHANG L H，KAMANNA V S，GANJI S H，et al. Niacin
[24] SAŁACKA A，BOROŃ A，GORĄCY I，et al. An associa‐ increases HDL biogenesis by enhancing DR4-dependent
tion of ABCG8：rs11887534 polymorphism and HDL- transcription of ABCA1 and lipidation of apolipoprotein
cholesterol response to statin treatment in the Polish popu‐ A-I in HepG2 cells[J]. J Lipid Res，2012，53（5）：941-950.
lation[J]. Pharmacol Rep，2021，73（6）：1781-1786. [37] HU M，CHU W C，YAMASHITA S，et al. Liver fat reduc‐
[25] LIU M Y，FAN F F，ZHANG Y，et al. The association of tion with niacin is influenced by DGAT-2 polymorphisms
GATM polymorphism with statin-induced myopathy：a in hypertriglyceridemic patients[J]. J Lipid Res，2012，53
systematic review and meta-analysis[J]. Eur J Clin Phar‐ （4）：802-809.
macol，2021，77（3）：349-357. [38] HU M，YANG Y L，NG C F，et al. Effects of phenotypic
[26] CHAPMAN M J. Fibrates in 2003：therapeutic action and genotypic factors on the lipid responses to niacin in
in atherogenic dyslipidaemia and future perspectives[J]. Chinese patients with dyslipidemia[J]. Medicine （Balti‐
Atherosclerosis，2003，171（1）：1-13. more），2015，94（20）：e881.
[27] HOUSE J S，MOTSINGER-REIF A A. Fibrate pharmaco- [39] BAE J W，CHOI C I，LEE J H，et al. Effects of UDP-
genomics：expanding past the genome[J]. Pharmacoge‐ glucuronosyltransferase polymorphisms on the pharmaco‐
nomics，2020，21（4）：293-306. kinetics of ezetimibe in healthy subjects[J]. Eur J Clin
[28] LIU Y J，ORDOVAS J M，GAO G M，et al. Pharmaco- Pharmacol，2011，67（1）：39-45.
genetic association of the APOA1/C3/A4/A5 gene cluster [40] ALTMANN S W，DAVIS H R Jr，ZHU L J，et al.
and lipid responses to fenofibrate：the genetics of lipid- Niemann-Pick C1 Like 1 protein is critical for intestinal
lowering drugs and diet network study[J]. Pharmacogenet cholesterol absorption[J]. Science，2004，303（5661）：
Genomics，2009，19（2）：161-169. 1201-1204.
[29] WOJCZYNSKI M K，GAO G M，BORECKI I，et al. [41] LOU X Y，QIN C Z，BAO M H，et al. Analysis of
Apolipoprotein B genetic variants modify the response to Niemann-Pick C1-like 1 （NPC1L1） genetic polymor‐
fenofibrate：a GOLDN study[J]. J Lipid Res，2010，51 phisms and haplotypes in Chinese Han population[J].
（11）：3316-3323. Pharmazie，2015，70（9）：581-585.
[30] TSAI M Y，ORDOVAS J M，LI N，et al. Effect of fenofi‐ [42] ZSÍROS N，BODOR M，VARGA V，et al. The c.-133A ＞
brate therapy and ABCA1 polymorphisms on high-density G polymorphism in NPC1L1 gene influences the efficacy
lipoprotein subclasses in the Genetics of Lipid Lowering of ezetimibe monotherapy on apolipoprotein A1 in hyper‐
Drugs and Diet Network[J]. Mol Genet Metab，2010，100 lipidemic patients[J]. Pharmazie，2014，69（6）：424-429.
（2）：118-122. [43] PISCIOTTA L，FASANO T，BELLOCCHIO A，et al. Ef‐
[31] LIU Y J，ORDOVAS J M，GAO G M，et al. The SCARB1 fect of ezetimibe coadministered with statins in genotype-
gene is associated with lipid response to dietary and confirmed heterozygous FH patients[J]. Atherosclerosis，
pharmacological interventions[J]. J Hum Genet，2008，53 2007，194（2）：e116-e122.
（8）：709-717. [44] BERTHOLD H K，LAAKSONEN R，LEHTIMÄKI T，
[32] SHEN J，ARNETT D K，PARNELL L D，et al. The effect et al. SREBP-1c gene polymorphism is associated with
of CYP7A1 polymorphisms on lipid responses to fenofi‐ increased inhibition of cholesterol-absorption in response
brate[J]. J Cardiovasc Pharmacol，2012，59（3）：254-259. to ezetimibe treatment[J]. Exp Clin Endocrinol Diabetes，
[33] CARLSON L A. Nicotinic acid：the broad-spectrum lipid 2008，116（5）：262-267.
drug. A 50th anniversary review[J]. J Intern Med，2005， [45] KAWAMURA R，SAIKI H，TADA H，et al. Acute myocar‐
258（2）：94-114. dial infarction in a 25-year-old woman with sitosterolemia
[34] ASLIBEKYAN S，STRAKA R J，IRVIN M R，et al. [J]. J Clin Lipidol，2018，12（1）：246-249.
Pharmacogenomics of high-density lipoprotein-cholesterol- [46] TADA H，NOHARA A，INAZU A，et al. Sitosterolemia，
raising therapies[J]. Expert Rev Cardiovasc Ther，2013，11 hypercholesterolemia，and coronary artery disease[J]. J
（3）：355-364. Atheroscler Thromb，2018，25（9）：783-789.
[35] TUTEJA S，WANG L，DUNBAR R L，et al. Genetic coding （收稿日期：2022-10-20 修回日期：2023-03-24）
variants in the niacin receptor，hydroxyl-carboxylic acid （编辑：唐晓莲）
receptor 2，and response to niacin therapy[J]. Pharmaco‐

· 1152 · China Pharmacy 2023 Vol. 34 No. 9 中国药房 2023年第34卷第9期